550. Clinical impact of Tocilizumab therapy in SARS-CoV-2 respiratory infections in ICU and non-ICU patients

BACKGROUND: Tocilizumab (TCZ) is a monoclonal antibody against the interleuikin-6 receptor which is potentially beneficial in COVID-19 induced cytokine release syndrome (CRS). However, there are limited studies showing anti-inflammatory effect and clinical benefit of TCZ in COVID-19 patients. This r...

Descripción completa

Detalles Bibliográficos
Autores principales: Vyas, Nikunj M, Hou, Cindy, Levin, Todd P, Fussa, Mark, DeRose, Joseph, Condoluci, Mark, Williams, James, Ghayad, Zeina, Barnish, Michael, Ali, Shereef N, Kerr, Kathryn H, Scheiblein, Scott W, Fryckberg, Anthony J, Chauhan, Gauri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777636/
http://dx.doi.org/10.1093/ofid/ofaa439.744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777636/
http://dx.doi.org/10.1093/ofid/ofaa439.744

Ejemplares similares